Wharton S, le Roux CW, Bozkurt B, Platz E, et al. Baseline characteristics in the SYNCHRONIZE-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes. Diabetes Obes Metab 2025 Nov 11. doi: 10.1111/dom.70263.
PMID: 41216778